BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 30, 2012
View Archived Issues
Evotec and Probiodrug enter development collaboration for novel enzyme target
Read More
Kythera's ATX-101 is safe in interim study results
Read More
Proof-of-concept results reported for BAY-94-8862
Read More
Starpharma reports data from two phase III VivaGel studies
Read More
PAX2 identified in CNS hemangioblastomas
Read More
Shionogi & Co. presents new NPY5 receptor antagonists
Read More
RVX-297 reduces clinical signs of disease in a rat model of rheumatoid arthritis
Read More
First-in-human study of AT-406 described
Read More
Novel PDE10 inhibitors disclosed by Mochida Pharmaceutical
Read More
Exelixis prepares new iPFK2 inhibitors for cancer
Read More
Curis licenses GDC-0917 from Genentech
Read More
Shionogi & Co. presents new BACE1 inhibitors
Read More
Merck & Co. updates on ridaforolimus MAA
Read More
Japan Tobacco designs novel RORgamma antagonists
Read More
Protalex treats first patient phase Ib PRTX-100 trial
Read More
MM-938 significantly reduces tumor growth rates in glioblastoma mouse models
Read More
Novel protein kinase inhibitors patented by Abbott Laboratories
Read More
Nordic Pharma gains marketing rights for Veregen in certain countries
Read More
Preclinical and phase I data presented for AP-26113
Read More
Bayer and Leiden University to coordinate drug discovery consortium
Read More
Tekmira acquires license to RNAi technology
Read More
Phase II trial of pancreas cancer vaccines completes enrollment
Read More
Immunovative Therapies receives clearance for phase II/III trial in Thailand
Read More
Novel mouse model of NSF developed at Thomas Jefferson University
Read More
FDA approves Cometriq, EMA accepts MAA
Read More
Enrollment complete in pivotal U.S. phase III trial of NX-1207
Read More
